Advertisement
RayzeBio Inc. Common Stoc... (RYZB)
NASDAQ: RYZB
· Real-Time Price · USD
62.49
0.01 (0.02%)
At close: Feb 23, 2024, 9:00 PM
0.02% (1D)
| Bid | n/a |
| Market Cap | 3.75B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -53.34M |
| EPS (ttm) | -1.08 |
| PE Ratio (ttm) | -57.861111111111114 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 282,719 |
| Avg. Volume (20D) | 745,490 |
| Open | 62.49 |
| Previous Close | 62.48 |
| Day's Range | 62.48 - 62.50 |
| 52-Week Range | 17.95 - 62.51 |
| Beta | 3.79 |
About RYZB
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the pe...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 15, 2023
Employees 88
Stock Exchange NASDAQ
Ticker Symbol RYZB